三氟美嗪 | 2622-37-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 三氟美嗪
• 英文名称: Trifluomeprazin
• 英文别名: Trifluomeprazine；N,N,2-trimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine
• CAS: 2622-37-9
• 化学式: C₁₉H₂₁F₃N₂S
• 分子量: 366.45
• InChiKey: ILBBYVOOXMPNTM-UHFFFAOYSA-N

物化性质

• 沸点：
  435.4±45.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)
• 保留指数：
  2250

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  31.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  三氟美嗪 、 硫酸二甲酯 生成 2-三氟甲基吩噻嗪
  参考文献：
  名称：

  JAKFALVI, E.;GELEGONYA, G.;PATAKI, S.;BIRO, I.;TAKACS, Z.

  摘要：

  DOI：

文献信息

• [EN] CARCAINIUM SALTS<br/>[FR] SELS DE CARCAÏNIUM
  申请人：VERONA PHARMA PLC

  公开号：WO2014037727A1

  公开（公告）日：2014-03-13

  A pharmaceutically acceptable addition salt of (i) carcainium, and (ii) oxalic acid, fumaric acid, maleic acid orhydrobromic acid.

  (i) 草果碱和(ii) 草酸、富马酸、马来酸或溴酸的药用可接受的加盐物。
• [EN] SYNTHETIC PROCESS FOR TRANS-AMINOCYCLOHEXYL ETHER COMPOUNDS<br/>[FR] METHODE DE SYNTHESE POUR COMPOSES DE TRANS-AMINOCYCLOHEXYL ETHER
  申请人：CARDIOME PHARMA CORP

  公开号：WO2005016242A2

  公开（公告）日：2005-02-24

  This invention is directed to methods of stereoselectively preparing, from appropriately substituted starting materials and reagents, an aminocyclohexyl ether of the formula (57) or the formula (75): where R1, R2, R3, R4 and R5 are defined herein. The compounds of formula (57) and formula (75) are useful in treating medical conditions or disorders, including, for example, cardica arrhythmias such as atrial arrhythmia and ventricular arrhythmia.

  本发明涉及一种立体选择性制备公式（57）或公式（75）的氨基环己基醚的方法，所述方法从适当的取代起始材料和试剂出发。其中R1、R2、R3、R4和R5在此定义。公式（57）和公式（75）的化合物在治疗医疗状况或疾病方面具有用途，包括例如心脏心律失常如房性心律失常和室性心律失常。
• Synthetic process for trans-aminocyclohexyl ether compounds
  申请人：Barrett G. M. Anthony

  公开号：US20050038256A1

  公开（公告）日：2005-02-17

  A method of stereoselectively making an aminocyclohexyl ether comprises, for example, reacting to form the aminocyclohexyl ether having the formula respectively, wherein independently at each occurrence, R 1 and R 2 are independently hydrogen, C 1 -C 8 alkyl, C 3 -C 8 alkoxyalkyl, C 1 -C 8 hydroxyalkyl, or C 7 -C 12 aralkyl; or R 1 and R 2 are independently C 3 -C 8 alkoxyalkyl, C 1 -C 8 hydroxyalkyl, and C 7 -C 12 aralkyl; or R 1 and R 2 , when taken together with the nitrogen atom to which they are directly attached in formula (57) or (75), form a ring denoted by formula (I): wherein the ring of formula (I) is formed from the nitrogen as shown as well as three to nine additional ring atoms independently carbon, nitrogen, oxygen, or sulfur; where any two adjacent ring atoms may be joined together by single or double bonds, and where any one or more of the additional carbon ring atoms may be substituted with one or two substituents selected from the group consisting of hydrogen, hydroxy, C 1 -C 3 hydroxyalkyl, oxo, C 2 -C 4 acyl, C 1 -C 3 alkyl, C 2 -C 4 alkylcarboxy, C 1 -C 3 alkoxy, and C 1 -C 20 alkanoyloxy, or may be substituted to form a spiro five- or six-membered heterocyclic ring containing one or two oxygen and/or sulfur heteroatoms; or any two adjacent additional carbon ring atoms may be fused to a C 3 -C 8 carbocyclic ring, and any one or more of the additional nitrogen ring atoms may be substituted with substituents selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 4 acyl, C 2 -C 4 hydroxyalkyl and C 3 -C 8 alkoxyalkyl; or R 1 and R 2 , when taken together with the nitrogen atom to which they are directly attached in formula (I), may form a bicyclic ring system selected from the group consisting of 3-azabicyclo[3.2.2]nonan-3-yl, 2-azabicyclo[2.2.2]octan-2-yl, 3-azabicyclo[3.1.0]hexan-3-yl, and 3-azabicyclo[3.2.0]heptan-3-yl; and wherein R 3 , R 4 and R 5 are independently bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, cyano, sulfamyl, trifluoromethyl, C 2 -C 7 alkanoyloxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 2 -C 7 alkoxycarbonyl, C 1 -C 6 thioalkyl, aryl or N(R 6 ,R 7 ) where R 6 and R 7 are independently hydrogen, acetyl, methanesulfonyl or C 1 -C 6 alkyl; or R 3 , R 4 and R 5 are independently hydrogen, hydroxy or C 1 -C 6 alkoxy; with the proviso that R 3 , R 4 and R 5 cannot all be hydrogen; and wherein O-J is a leaving group. Methods of making intermediates are also disclosed.

  一种立体选择性制备氨基环己醚的方法，例如，反应生成具有以下式子的氨基环己醚，其中在每个出现的位置上，独立的R1和R2分别为氢、C1-C8烷基、C3-C8烷氧基烷基、C1-C8羟基烷基或C7-C12芳基烷基；或者独立的R1和R2为C3-C8烷氧基烷基、C1-C8羟基烷基和C7-C12芳基烷基；或者R1和R2与它们直接连接的氮原子一起形成由以下式子表示的环：其中式子（I）的环由氮原子形成，以及三到九个独立的环原子，包括碳、氮、氧或硫；任意相邻的两个环原子可以通过单键或双键连接在一起，任何一个或多个额外的碳环原子可以被氢、羟基、C1-C3羟基烷基、氧代、C2-C4酰基、C1-C3烷基、C2-C4烷基羧基、C1-C3烷氧基或C1-C20烷酰氧基中的一个或两个取代，或者被取代以形成一个螺五元或六元杂环环，其中包含一个或两个氧和/或硫杂原子；任意相邻的两个额外碳环原子可以融合到一个C3-C8碳环中，任何一个或多个额外的氮环原子可以被氢、C1-C6烷基、C2-C4酰基、C2-C4羟基烷基和C3-C8烷氧基烷基中的一个或多个取代；或者R1和R2与它们直接连接的氮原子一起形成从以下组中选择的双环系统：3-氮杂双环[3.2.2]壬烷-3-基、2-氮杂双环[2.2.2]辛烷-2-基、3-氮杂双环[3.1.0]己烷-3-基和3-氮杂双环[3.2.0]庚烷-3-基；其中R3、R4和R5独立地为溴、氯、氟、羧基、氢、羟基、羟甲基、甲磺酰胺基、硝基、氰基、磺酰胺基、三氟甲基、C2-C7烷酰氧基、C1-C6烷基、C1-C6烷氧基、C2-C7烷氧羰基、C1-C6硫代烷基、芳基或N（R6，R7），其中R6和R7独立地为氢、乙酰、甲磺酰或C1-C6烷基；或者R3、R4和R5独立地为氢、羟基或C1-C6烷氧基；但是R3、R4和R5不能都为氢；O-J是一个离去基团。还公开了制备中间体的方法。
• [EN] AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSES A BASE D'AMINOCYCLOHEXYLE-ETHER ET LEURS UTILISATIONS
  申请人：CARDIOME PHARMA CORP

  公开号：WO2004099137A1

  公开（公告）日：2004-11-18

  Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.

  本发明披露了氨基环己醚化合物。本发明的化合物可以被纳入到组合物和试剂盒中。本发明还披露了化合物和组合物的用途，包括治疗心律不齐。
• Aminocyclohexyl ether compounds and uses thereof
  申请人：Cardiome Pharma Corp.

  公开号：EP2298735A1

  公开（公告）日：2011-03-23

  Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.

  本发明揭示了氨基环己基醚化合物。本发明的化合物可以被纳入组合物和试剂盒中。本发明还揭示了化合物和组合物的用途，包括治疗心律失常。

表征谱图